Form4insider filings, from the source

SEC Form 4 · accession 0000899243-17-005266

Aimmune Therapeutics, Inc. · AIMT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Stephen George Dilly
Officer — See Remarks · Director
Period of report
Feb 24, 2017
Accepted (ET)
Feb 24, 2017 · 6:38 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631650

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common Stock, $0.0001 par valueF1holding———715,308D
Common Stock, $0.0001 par valueF2holding———51,403IBy GRAT 1
Common Stock, $0.0001 par valueF3holding———14,447IBy GRAT 2
Common Stock, $0.0001 par valueF4holding———51,403IBy Wife's GRAT 1
Common Stock, $0.0001 par valueF5holding———14,447IBy Wife's GRAT 2

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (right to buy)F6$19.63Feb 24, 2017A240,000A—Feb 24, 2027Common Stock240,000240,000D

Explanation of responses

Remarks

President and Chief Executive Officer